SEC Form 4 · accession 0001179110-17-001962
IDERA PHARMACEUTICALS, INC. · IDRA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jonathan Michael Yingling
Officer — SVP of Early Development
Period of report
Feb 6, 2017
Accepted (ET)
Feb 8, 2017 · 4:45 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000861838
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionF1 | $1.55 | Feb 6, 2017 | A | 325,000 | A | — | Feb 6, 2027 | Common Stock | 325,000 | 325,000 | D |
| Stock OptionF2 | $1.55 | Feb 6, 2017 | A | 275,000 | A | — | Feb 6, 2027 | Common Stock | 275,000 | 275,000 | D |
Explanation of responses
- F1This option was granted under the Company's Stock Incentive Plan. The option vests with respect to 25% of the underlying shares on the first anniversary of the date of grant and the balance of the underlying shares vests in twelve equal quarterly installments following the first anniversary date of the date of grant.
- F2This option was not granted pursuant to any pre-existing equity plan of the Company. Instead, this option was made as an inducement grant pursuant to Nasdaq Listing Rule 5635(c)(4)in connection with the reporting person's appointment as Senior Vice President, Early Development. The options vest with respect to 25% of the underlying shares on the first anniversary date of the date of grant and the balance of the underlying shares vests in twelve quarterly installments following the first anniversary of the date of grant.